News

Stewart explains recent advances in eosinophilic gastrointestinal diseases and breaks down new ACG EoE guidelines.

A study links paternal prepubertal passive smoke exposure to impaired lung function in offspring.

Hosts explore the latest findings on GLP-1 medications, semaglutide and tirzepatide, from ESC Congress 2025.

Despite not lowering cardiovascular death or worsening heart failure, composite data did suggest the efficacy of in-hospital initiation of SGLT2 inhibitors.

NB-UVB phototherapy was highlighted in this study, with positive findings suggesting the treatment is an effective oral cyclosporine alternative.

Fava discusses promising phase 2b trial findings: a single 100 μg dose of MM120 rapidly reduces GAD symptoms by day 2, with benefits lasting 12 weeks.

A lower incidence of all-cause mortality and hospitalization for worsening heart failure proved digitoxin’s noninferiority in this phase 4 trial.

August 2025 saw a number of novel approvals and expert perspectives for World Lung Cancer Day.

Agios announces a 3-month extension for mitapivat's FDA review.

Investigators highlighted the cardiovascular safety of systemic treatments for psoriasis such as methotrexate and tumor necrosis factor inhibitors.

Patel addresses the updated AHA/ACC hypertension guidelines, explaining important features and highlighting the potential of newer therapies.

A phase 2b trial finds a single 100 μg dose of MM120 reduced GAD symptoms with benefits lasting 12 weeks, highlighting the promise of psychedelic therapy.

Amlitelimab met its primary and key secondary endpoints in the COAST 1 phase 3 study of adults and adolescents with atopic dermatitis.

This analysis highlights bimekizumab’s impact on psoriasis clearance compared to ustekinumab, secukinumab, and adalimumab.

A 30-week trial found weekly semaglutide reduced HbA1c while improving physical quality of life in patients on antipsychotics.

Findings highlight a 33% increase in 1-year and nearly 50% increase in 5-year post-transplant survival with a living versus deceased donor transplant.

Bhalla breaks down the newer treatments included in the recently updated AHA/ACC hypertension management guidelines.

A recap 8 clinical trials in cardiovascular care to know from the European Society of Cardiology Congress 2025.

A study shows that sex modifies HRQL outcomes in peanut OIT: males benefit most from active treatment, while females show strong placebo gains.

Salvatore Viscomi, MD, warns CKDu is a growing global health crisis, driven by heat stress, toxins, and occupational risks in vulnerable populations.

This announcement regarding the new sNDA for roflumilast cream in pediatric patients with psoriasis follows positive findings from the MUSE study.

Patients with hypercholesterolemia on individualized maximally tolerated dose of statins achieved guideline-recommended LDL-C levels on inclisiran.

This study highlighted VTE risk factors in a cohort of patients with alopecia areata who were eligible for baricitinib treatment.

WVE-006 drove production of M-AAT, which is protective of lung function, and reduced mutant Z-AAT, a cause of liver disease.

The TETON-2 study met its primary endpoint, significantly improveing lung function in IPF.

Cluster protocol VIT demonstrates high efficacy in children with venom allergies, showing low systemic reactions and strong protection against re-stings.

Check out renal FDA news and new research on pediatric kidney stone management, CKD trends, spironolactone for dialysis patients, and more.